Search
erenumab (Aimovig)
Indications:
- prevention of episodic migraine (FDA-approved May 2018) [3]
* may be useful when other preventive treatments have failed [4]
* may be useful for non-opioid medication overuse headache in patients with chronic migraine [7]
* safe & effective in preventing migraine with aura [6]
Dosage:
- 70 or 140 mg SQ monthly
Adverse effects:
- hypertension
- constipation
Mechanism of action:
- CGRP inhibitor
- humanized monoclonal antibody targeting CGRP (calcitonin gene-related peptide)
Clinical trials:
LIBERTY study
- failure of 2-4 previous migraine prophylaxis treatments
- 30% of patients achieved 50% reduction in migrain days with erenumab [2]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
calcitonin gene-related peptide (CGRP) inhibitor
References
- Goadsby PJ, Reuter U, Hallstrom Y et al
A Controlled Trial of Erenumab for Episodic Migraine.
N Engl J Med 2017; 377:2123-2132. Nov 30, 2017
PMID: 29171821
http://www.nejm.org/doi/full/10.1056/NEJMoa1705848
- George J
Erenumab Reduces Migraine in Hard-to-Treat Patients.
But questions about long-term risks remain unanswered.
MedPage Today. April 17, 2018
https://www.medpagetoday.com/meetingcoverage/aan/72398
- Reuter U, et al.
Efficacy and safety of erenumab in episodic migraine patients
with 2-4 prior preventive treatment failures: Results from
the Phase 3b LIBERTY study.
American Academy of Neurology (AAN) 2018.
- Brauser D.
FDA Approves First-in-Class Drug Erenumab (Aimovig) for
Migraine Prevention.
Medscape - May 17, 2018.
https://www.medscape.com/viewarticle/896851
- FDA News Release. May 17, 2018
FDA approves novel preventive treatment for migraine.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm608120.htm
- Reuter U, Goadsby PJ, Lanteri-Minet M et al
Efficacy and tolerability of erenumab in patients with episodic
migraine in whom two-to-four previous preventive treatments were
unsuccessful: a randomised, double-blind, placebo-controlled,
phase 3b study.
Lancet Oct 22, 2018
Reuter U, Goadsby PJ, Lanteri-Minet M
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32534-0/fulltext
- Charles A
A new opportunity after migraine treatment failure?
Lancet Oct 22, 2018
PMID: 30360967
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32606-0/fulltext
- George J
New Safety Concern for Migraine Drug?
FDA: hypertension seen in some erenumab patients
https://www.medpagetoday.com/neurology/migraines/90805
- Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C.
Hypertension: A new safety risk for patients treated with erenumab.
Headache 2021. Jan 10
PMID: 33423274
https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14051
- Whitlock Burton K
Erenumab Safe, Effective in Preventing Migraine With Aura.
Medscape. December 20, 2021
https://www.medscape.com/viewarticle/965194
- Tepper SJ, Dodick DW, Lanteri-Minet M et al
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in
Chronic Migraine: A Phase 4, Randomized, Placebo-Controlled Trial.
JAMA Neurol. 2024 Sep 16:e243043.
PMID: 39283627 PMCID: PMC11406451 Free PMC article.
https://jamanetwork.com/journals/jamaneurology/fullarticle/2823594
- HIGHLIGHTS OF PRESCRIBING INFORMATION
AIMOVIG (erenumab-aooe) injection, for subcutaneous use
https://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/aimovig/aimovig_pi_hcp_english.ashx